Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02149108
Registration number
NCT02149108
Ethics application status
Date submitted
26/05/2014
Date registered
29/05/2014
Date last updated
21/07/2017
Titles & IDs
Public title
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Query!
Scientific title
A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.
Query!
Secondary ID [1]
0
0
2012-000095-42
Query!
Secondary ID [2]
0
0
1199.52
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Colorectal Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Experimental: Nintedanib (BIBF 1120) + BSC -
Placebo comparator: Placebo + BSC -
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS) by Central Review Assessment
Query!
Assessment method [1]
0
0
PFS by central review assessment was defined as the time from the date of randomisation to the date of disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or death from any cause, whichever occurred first.
Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Query!
Timepoint [1]
0
0
From randomisation until cut-off date 14JUN2016.
Query!
Primary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
OS was defined as the time from randomisation to the time of death from any cause.
Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Query!
Timepoint [2]
0
0
From randomisation until cut-off date 14JUN2016.
Query!
Secondary outcome [1]
0
0
Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment
Query!
Assessment method [1]
0
0
Objective tumour response was defined as best overall response of CR or PR determined by central review assessment.
Query!
Timepoint [1]
0
0
From randomisation until cut-off date 14JUN2016.
Query!
Secondary outcome [2]
0
0
Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment
Query!
Assessment method [2]
0
0
Disease control was defined as best overall response of CR, PR, or Stable Disease (SD).
Query!
Timepoint [2]
0
0
From randomisation until cut-off date 14JUN2016.
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
* Age >= 18 years
* Signed informed consent
* Histologically or cytologically confirmed colorectal adenocarcinoma
* Metastatic or locally advanced disease not amenable to curative surgery and/or radiotherapy
* Eastern Cooperative Oncology Group (ECOG) performance status = 1
* At least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
* Progression on standard therapies or withdrawn from standard treatment due to unacceptable toxicity. Previous standard treatment must include all of the following:
* - fluoropyrimidine
* - oxaliplatin: Patients treated with oxaliplatin in adjuvant setting should have progressed within 6 months of completion of adjuvant therapy or they must have been treated with oxaliplatin for metastatic disease
* - irinotecan
* - bevacizumab or aflibercept
* - cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumours
* - The remaining standard available therapy as recommended by investigator is best supportive care (note: previous treatment with regorafenib and TAS 102 are allowed and these agents should be administered before study if available to patient according to local standards)
* - Life expectancy of at least 12 weeks
* - Hepatic function: aspartate aminotransferase (AST)/ Alanine Amino Transferase (ALT) = 1.5 X Upper Limit of Normal (ULN) and bilirubin = ULN for patients without liver metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver metastases. Patients with Gilbert syndrome and bilirubin < 2 X ULN and normal AST/ALT are eligible
* Coagulation parameters: International normalised ratio (INR) < 2 and partial prothrombin Time (PTT) = 2xULN
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
* Previous treatment with nintedanib
* toxicity attributed to previous anticancer therapy that did not resolve to Common Terminology Criteria for Adverse Events (CTCAE) grade =1
* History of other malignancies in the last 5 years, in particular those that could interfere with interpretation of results.
* Serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug,
* Significant cardiovascular diseases
* History of severe haemorrhagic or thromboembolic event in the past 12 months
* Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or similar agents requiring therapeutic INR monitoring
* Gastrointestinal disorders or abnormalities that would interfere with absorption of study drug
* Patient with brain metastases that are symptomatic and/or require therapy.
* Patients of childbearing potential who are sexually active and unwilling to use a highly effective method of contraception
* Pregnancy or breast-feeding.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/09/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
25/08/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
768
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
1199.52.6102 Boehringer Ingelheim Investigational Site - Concord
Query!
Recruitment hospital [2]
0
0
1199.52.6103 Boehringer Ingelheim Investigational Site - St Leonards
Query!
Recruitment hospital [3]
0
0
1199.52.6101 Boehringer Ingelheim Investigational Site - Wollongong
Query!
Recruitment hospital [4]
0
0
1199.52.6104 Boehringer Ingelheim Investigational Site - Heidelberg
Query!
Recruitment hospital [5]
0
0
1199.52.6105 Boehringer Ingelheim Investigational Site - Nedlands
Query!
Recruitment hospital [6]
0
0
1199.52.6106 Boehringer Ingelheim Investigational Site - Perth
Query!
Recruitment postcode(s) [1]
0
0
- Concord
Query!
Recruitment postcode(s) [2]
0
0
- St Leonards
Query!
Recruitment postcode(s) [3]
0
0
- Wollongong
Query!
Recruitment postcode(s) [4]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [5]
0
0
- Nedlands
Query!
Recruitment postcode(s) [6]
0
0
- Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Iowa
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kansas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Nebraska
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Cdad. de Córdoba
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Ciudad Autónoma de Bs As
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Linz
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Wien
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Aalst
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Bonheiden
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Bruxelles
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Charleroi
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Edegem
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Haine-Saint-Paul
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Leuven
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Liège
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Luxembourg
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
British Columbia
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Ontario
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Quebec
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Brno
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Hradec Kralove
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Prague
Query!
Country [32]
0
0
Denmark
Query!
State/province [32]
0
0
Herning
Query!
Country [33]
0
0
Denmark
Query!
State/province [33]
0
0
København Ø
Query!
Country [34]
0
0
Denmark
Query!
State/province [34]
0
0
Næstved
Query!
Country [35]
0
0
Denmark
Query!
State/province [35]
0
0
Odense C
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Lille cedex
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Lyon cedex 8
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Paris cedex 15
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Reims Cedex
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Dresden
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Essen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Freiburg
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Mannheim
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Ulm
Query!
Country [45]
0
0
Hong Kong
Query!
State/province [45]
0
0
Hong Kong
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Beer Sheva
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Petach Tikva
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Tel Aviv
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Genova
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Milano
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Napoli
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Padova
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Pisa
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
San Giovanni Rotondo (FG)
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Aichi, Nagoya
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Chiba, Chiba
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Chiba, Kashiwa
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Ehime, Matsuyama
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Fukuoka, Fukuoka
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Hokkaido, Sapporo
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Hyogo, Amagasaki
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Hyogo, Kobe
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Ibaraki, Tsukuba
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Oita, Yufu
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Osaka, Osaka
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Osaka, Suita
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Saitama, Kitaadachi-gun
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Shizuoka, Sunto-gun
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Tokyo , Shinagawa-ku
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Tokyo, Koto-ku
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Goyang
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Seoul
Query!
Country [73]
0
0
Mexico
Query!
State/province [73]
0
0
Mexico
Query!
Country [74]
0
0
Netherlands
Query!
State/province [74]
0
0
Amsterdam
Query!
Country [75]
0
0
Netherlands
Query!
State/province [75]
0
0
Utrecht
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Jelenia Gora
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Poznan
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Wroclaw
Query!
Country [79]
0
0
Portugal
Query!
State/province [79]
0
0
Almada
Query!
Country [80]
0
0
Portugal
Query!
State/province [80]
0
0
Coimbra
Query!
Country [81]
0
0
Portugal
Query!
State/province [81]
0
0
Loures
Query!
Country [82]
0
0
Portugal
Query!
State/province [82]
0
0
Porto
Query!
Country [83]
0
0
Russian Federation
Query!
State/province [83]
0
0
Moscow
Query!
Country [84]
0
0
Russian Federation
Query!
State/province [84]
0
0
St. Petersburg
Query!
Country [85]
0
0
Russian Federation
Query!
State/province [85]
0
0
Tyumen
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Barcelona
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
L'Hospitalet de Llobregat
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
La Coruña
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Madrid
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Santander
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Sevilla
Query!
Country [92]
0
0
Sweden
Query!
State/province [92]
0
0
Stockholm
Query!
Country [93]
0
0
Sweden
Query!
State/province [93]
0
0
Uppsala
Query!
Country [94]
0
0
Taiwan
Query!
State/province [94]
0
0
Kaohsiung
Query!
Country [95]
0
0
Taiwan
Query!
State/province [95]
0
0
Taipei
Query!
Country [96]
0
0
Taiwan
Query!
State/province [96]
0
0
Taoyuan County
Query!
Country [97]
0
0
Turkey
Query!
State/province [97]
0
0
Adana
Query!
Country [98]
0
0
Turkey
Query!
State/province [98]
0
0
Ankara
Query!
Country [99]
0
0
Turkey
Query!
State/province [99]
0
0
Antalya
Query!
Country [100]
0
0
Turkey
Query!
State/province [100]
0
0
Istanbul
Query!
Country [101]
0
0
Turkey
Query!
State/province [101]
0
0
Izmir
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Aberdeen
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Manchester
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Middlesex
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Nottingham
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02149108
Query!
Trial related presentations / publications
Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limon ML, Saunders M, Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F, Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Ann Oncol. 2018 Sep 1;29(9):1955-1963. doi: 10.1093/annonc/mdy241. Van Cutsem E, Yoshino T, Hocke J, Oum'Hamed Z, Studeny M, Tabernero J. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment. Clin Colorectal Cancer. 2016 Mar;15(1):91-94.e1. doi: 10.1016/j.clcc.2015.09.005. Epub 2015 Oct 9.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02149108
Download to PDF